Chinese
Japan
English
Currently, most therapeutic antibody discovery strategies start by screening for binders, followed by purification of these antibodies for further functional characterization. However, massive resources are invested into the time-consuming step-by-step screening schema, and arbitrary selection of candidates purely based on binding capability further compromises diversity.
In this white paper, we will discuss solutions that can be applied to current antibody discovery platforms to overcome this issue and significantly improve process efficiency.
COVERED IN THIS WHITE PRPER
* I agree to the Terms of Use and Privacy Policy
I agree to receive the latest news, information, promotions, webinars and services, and acknowledge that I can opt out any time.